Low-penetration, high-growth market: Data shows that from 2023 to 2025, the sales volume of orthopedic surgical robots in domestic public procurement increased from 58 units to 115 units, nearly doubling. Market analysis suggests that the industry's growth rate is expected to remain around 40% from 2024 to 2026, significantly higher than the global average.
Beyond industrial consolidation and centralized procurement policies, the commercialization of orthopedic surgical robots themselves has also entered a critical period.
A low-penetration, high-growth market: Data shows that between 2023 and 2025, the sales volume of publicly procured orthopedic surgical robots in China increased from 58 to 115 units, nearly doubling. Market analysis suggests that from 2024 to 2026, the industry's scale growth rate is expected to remain at around 40% for consecutive years, far above the global average.
Medical insurance payment has become a key catalyst: The National Healthcare Security Administration has established a unified price item framework for orthopedic surgical robots, clearing obstacles for local authorities to set charging standards. As local charging and medical insurance payment policies are implemented at an accelerated pace, 2026-2027 is regarded as a critical window for commercial validation as orthopedic surgical robots move from "product approval" to "large-scale installation and use."
